期刊文献+

HER-2/neu胞外配体结合区基因的克隆及原核表达 被引量:6

Cloning and prokaryotic expression of HER-2/neu extracellular domain
下载PDF
导出
摘要 目的 克隆HER 2 /neu胞外配体结合区基因 ,并在大肠杆菌中获得高效表达。方法 用PCR技术扩增HER 2 /neu胞外配体结合区的cDNA片段 ,并将该片段插入pET 2 8a(+)原核表达载体中 ,实现插入基因的融合表达 ;用SDS PAGE和蛋白免疫印迹法分别测定表达产物的相对分子质量及特异性。结果 构建的重组质粒在大肠杆菌中获得高效稳定的表达 ,表达产物的相对分子质量与预期值一致 ,且所表达蛋白可被抗HER 2 /neu的特异性抗体识别。结论 获得了HER 2 /neu胞外配体结合区基因在原核系统中的表达 ,为HER 2 Objective To clone and express the gene of HER 2/neu ext racellular domain.Methods The cDNA fragment of HER 2/neu extra cellular domain was amplified by PCR, then cloned into the prokaryotic phagemid pET 28a(+) vector, and expressed as a fusion protein in E.coli . SDS PAGE a nd Western blotting were used to analyze the molecular weight and specificity o f the expressed protein. Results The recombinant protein was express ed highly and stably in E.coli , and the molecular weight of the expression p rodu ct was identical to the expected value. In addition, the protein expressed could react with the specific antibody against protooncoprotein HER 2/neu. Conclusion A plasmid containing HER 2/neu extracellular domain gene was constructed. The expression of the HER 2/neu extracellular protein was obtained in E.coli . It will be helpful to the study of the vaccine for the tumor ove rexpressing HER 2/neu oncoprotein.
出处 《免疫学杂志》 CAS CSCD 北大核心 2003年第3期183-185,189,共4页 Immunological Journal
基金 国家自然科学基金资助项目 (30 0 70 85 8)
关键词 HER-2/NEU 配体结合区 克隆 原核表达 原癌基因 HER 2/neu oncogene Receptor ligand domain Gene cloning Prokaryotic expression
  • 相关文献

参考文献10

  • 1Coussens L, Yang Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene [ J]. Science, 1985,230(4 730) : 1132- 1139.
  • 2Brennan PJ, Kumagai T, Berezov A, et al. HER2/neu:mechanisms of dimerization / oligomerization[ J ]. Oncogene,.2000, 19(53) :6093 - 6101.
  • 3Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situhybridization [J]. Proc Natl Acad Sci USA, 1992, 89(12):5321 - 5325.
  • 4Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of c-erbB2 expression in breast cancer[J] .J Surg Oncol, 2002,79(4) :216 - 223.
  • 5Lu J, Cells E. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes[J]. Cancer Res, 2000, 60(18):5223 - 5227.
  • 6Ward RL, Hawkins N J, Coomber D, et al. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer[J]. Hum Immunol, 1999, 60(6) :510 - 515.
  • 7Disis ML, Smith JW, Murphy AE, et al. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein [ J]. Cancer Res,1994, 54(4):1071 - 1076.
  • 8Kono K, Rongcun Y, Charo J, et al. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes[J]. Int J Cancer, 1998, 78(2) :202 - 208.
  • 9Disis ML, Cooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines[J]. J Clin Oneol,2002, 20(11): 2624 -2632.
  • 10Samanta A, LeVea CM, Dougall WC, et al. Ligand and p185c-neu density govem receptor interactions and tyrosine kinase activation [ J ]. Proc Nail Acad Sci USA, 1994,91(5):1711-1715.

同被引文献68

引证文献6

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部